Start-Up vs Big Pharma Operating Models: Speed, Control, and Cost in Clinical Development
Start-Up vs Big Pharma Operating Models: Speed, Control, and Cost in Clinical Development How Start-Ups and Big Pharma Really Run Trials—Balancing Speed, Control, and Cost Strategic DNA: how operating models shape decisions, risk, and evidence A startup clinical development model typically revolves around one to three assets, tight governance, and externalized execution. By contrast, Big…